-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Suzhou, China and Rockville, Maryland, U.
APG2575CC201 is a single-arm, open key registration phase II clinical study in R/R CLL/SLL patients to evaluate the effectiveness and safety of APG-2575
APG-2575 is a new type of oral Bcl-2 selective small molecule inhibitor under research by Ascent Pharmaceuticals, which can restore the programmed death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis , To achieve the purpose of treating tumors
There is still a huge unmet need for treatment in the global CLL/SLL treatment field
Dr.
About Lisaftoclax (APG-2575)
APG-2575 is a new type of oral Bcl-2 selective small molecule inhibitor under research by Ascent Pharmaceuticals, which can restore the programmed death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis , To achieve the purpose of treating tumors
APG-2575 has been carried out in the United States, China, Australia, Europe and other places around the world, including the treatment of chronic lymphocytic leukemia, acute myeloid leukemia, breast cancer, and other blood tumors and solid tumors clinical research
About Yasheng Pharmaceutical
Yasheng Pharmaceutical is a biomedical company based in China and facing the world.
Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world
Relying on strong R&D capabilities, Yasheng Pharmaceuticals has deployed intellectual property rights globally, and cooperated with leading biotechnology companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck, AstraZeneca, and Pfizer.
Forward-looking statement
The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article
Source: Yasheng Pharmaceutical
